Valeant Pharma (VRX) Files Preliminary Consent Solicitation for Cephalon Board Change

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) has filed a preliminary consent solicitation with the U.S. SEC.

The solicitation statement in connection with its solicitation of written consents from the Cephalon (Nasdaq: CEPH) stockholders to remove each member of the Board of Directors of Cephalon Inc. and elect seven new directors in their place.

The proposed directors are:

• Santo J. Costa, Former President and COO of Quintiles
  
  
• Richard H. Koppes, Former General Counsel and Interim CEO of CalPERS
  
  
• Lawrence N. Kugelman, Former CEO and President of Coventry Health Care
  
  
• Anders Lonner, Group President and CEO of Meda AB
  
  
• John H. McArthur, Former Dean of Harvard Business School
  
  
• Thomas G. Plaskett, Director of Alcon and RadioShack
  
  
• Blair H. Sheppard, Chair and former CEO of Duke Corporate Education and former Dean of Fuqua School of Business, Duke University

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Cosmos Health signs Saudi distribution deal for supplement line
• Ocean Power Technologies regains NYSE compliance after late 10-K filing
• Baird Medical wins two Pakistan product registrations for ablation gear